ATAI

#2139
AtaiBeckley Inc. Common Stock
4.3300 USD
-0.23%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
4.3300
4.3300
Faixa anual
3.2700
5.5000
Mudança diária
-0.23%
Mudança mensal
+28.49%
Mudança em 6 meses
+9.62%
Mudança anual
+9.62%
Fechamento anterior
4.3400
Abrir
4.3300
Mínimo
4.3300
High
4.3300
Volume
64
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 1.5794 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
-1.41
Índice preço/fluxo de caixa
226.59

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

Notícias